Trial · NCT02053350
Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection
NCT02053350, Phase 2, Terminated, University of Virginia; results first posted 2022-06-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection. Trials, record NCT02053350. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02053350
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection
- NCT number
- NCT02053350
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 7 participants, actual
- Lead sponsor
- University of Virginia
- Conditions
- Clostridium Difficile Infection
- Interventions
- Alanyl-glutamine
- First posted
- 2014-02-03
- Last updated
- 2022-06-07
- Results first posted
- 2022-06-07
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Recurrent C. Difficile Infection | At day forty | Day 40 clinical failure - clinical failure includes death or CDI recurrence assessed 40 days post randomization or lack of clinical cure |
| Primary | Mortality | Up to 6 months after end of treatment | Death from any cause at days 40, 70 and 190 |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Recurrent C. Difficile Infection | At day forty | Number of Participants with Recurrent C. Difficile Infection | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Mortality | Up to 6 months after end of treatment | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Recurrent C. Difficile Infection | Alanyl-glutamine | 1 | Participants | ||
| Mortality | Alanyl-glutamine | 0 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Alanyl-glutamine | 7 | |
| Overall Study | COMPLETED | Alanyl-glutamine | 2 | |
| Overall Study | NOT COMPLETED | Alanyl-glutamine | 5 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | gastrointestinal symptoms | Gastrointestinal disorders | Alanyl-glutamine | 4 | 7 | 4 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Alanyl-glutamine | 0 | 7 |
| Total, other adverse events | Alanyl-glutamine | 4 | 7 |
| Total, serious adverse events | Alanyl-glutamine | 0 | 7 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02053350
GET https://conductscience.org/api/trials/v1/NCT02053350/registered